{"nctId":"NCT00624052","briefTitle":"26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension","startDateStruct":{"date":"2008-03"},"conditions":["Hypertension"],"count":838,"armGroups":[],"interventions":[{"name":"fixed-dose combination of telmisartan 40mg+amlodipine 10mg","otherNames":[]},{"name":"fixed-dose combination of telmisartan 80mg+amlodipine10mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- diagnosis of essential hypertension\n\nExclusion Criteria:\n\n* pregnancy, breast-feeding, unwilling to use effective contraception (if female of child-bearing potential).\n* development of any condition in the preceding trial that could be worsened by telmisartan 40mg/amlodipine 10mg (T40/A10) or telmisartan 80mg/amlodipine 10mg (T80/A10).\n* discontinuation from the preceding trial.\n* known or suspected secondary hypertension.\n* mean seated systolic blood pressure (SBP) \\>= 180 mmHg and/or mean seated diastolic blood pressure (DBP) \\>= 120 mmHg at any visit.\n* any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant.\n* clinically relevant hyperkalaemia.\n* uncorrected volume or sodium depletion.\n* primary aldosteronism.\n* hereditary fructose or lactose intolerance.\n* symptomatic congestive heart failure.\n* patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).\n* any new drug or alcohol dependency since signing consent of the preceding trial.\n* concurrent participation in another clinical trial or any investigational therapy since completing the preceding trial.\n* hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve.\n* known allergic hypersensitivity to any component of the formulations under investigation. \\[Includes known hypersensitivity to telmisartan or other ARBs or amlodipine or other dihydropyridine calcium channel blockers (CCBs).\\] non-compliance with study medication (defined as \\<80% or \\>120%) during the preceding trial.\n* administration of ARBs or dihydropyridine CCBs (apart from trial medication). any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough Seated Diastolic Blood Pressure (DBP) Control","description":"The number of patients who reached the target DBP of \\<90mmHg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"201","spread":null},{"groupId":"OG001","value":"402","spread":null},{"groupId":"OG002","value":"72","spread":null},{"groupId":"OG003","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Seated Systolic Blood Pressure (SBP) Control","description":"The number of patients who reached the target SBP of \\>=140mmHg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":null},{"groupId":"OG001","value":"366","spread":null},{"groupId":"OG002","value":"70","spread":null},{"groupId":"OG003","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"21","spread":null},{"groupId":"OG003","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Study in Trough Seated Diastolic Blood Pressure","description":"Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.6","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.41","spread":"0.44"},{"groupId":"OG001","value":"-13.36","spread":"0.31"},{"groupId":"OG002","value":"-11.52","spread":"0.69"},{"groupId":"OG003","value":"-10.64","spread":"0.67"}]}]}]},{"type":"SECONDARY","title":"Change in DBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052","description":"The difference between the last available troughs represents the additional reduction in DBP in this study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.36","spread":"0.48"},{"groupId":"OG001","value":"-4.97","spread":"0.34"},{"groupId":"OG002","value":"-5.51","spread":"0.74"},{"groupId":"OG003","value":"-5.43","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Study in Trough Seated Systolic Blood Pressure","description":"Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.6","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.76","spread":"0.72"},{"groupId":"OG001","value":"-15.93","spread":"0.5"},{"groupId":"OG002","value":"-14.85","spread":"1.12"},{"groupId":"OG003","value":"-12.44","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Change in SBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052","description":"The difference between the last available troughs represents the additional reduction in SBP in this study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.73","spread":"0.73"},{"groupId":"OG001","value":"-6.02","spread":"0.51"},{"groupId":"OG002","value":"-6.55","spread":"1.11"},{"groupId":"OG003","value":"-5.61","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Trough Seated DBP Response","description":"The number of patients who reach the target DBP of \\<90mmHg or had a reduction in DBP \\>= 10mmHg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"201","spread":null},{"groupId":"OG001","value":"405","spread":null},{"groupId":"OG002","value":"71","spread":null},{"groupId":"OG003","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Seated SBP Response","description":"The number of patients who reach the target SBP of \\<140mmHg or had a reduction in SBP \\>= 15 mmHg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":null},{"groupId":"OG001","value":"401","spread":null},{"groupId":"OG002","value":"75","spread":null},{"groupId":"OG003","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough BP Normality Classes","description":"The number of patients who reach predefined BP categories","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"146","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"189","spread":null},{"groupId":"OG002","value":"46","spread":null},{"groupId":"OG003","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Additional Antihypertensive","description":"Time from first intake of medication to first intake of an antihypertensive other than the study drug","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.9","spread":"45.2"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control","description":"The number of patients with DBP control (DBP\\>=90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"121","spread":null}]}]}]},{"type":"SECONDARY","title":"Additional Reduction in DBP by Use of Additional Antihypertensive Therapy","description":"Difference in trough DBP from last visit before add-on therapy and last visit during NCT00624052","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.79","spread":"7.39"}]}]}]},{"type":"SECONDARY","title":"Additional Reduction in SBP by Use of Additional Antihypertensive Therapy","description":"Difference in trough SBP from last visit before add-on therapy and last visit during NCT00624052","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.79","spread":"12.37"}]}]}]},{"type":"SECONDARY","title":"Trough DBP Control Pre- and Post- Uptitration","description":"The number of patients with DBP control (DBP\\<90 mmHg). Last trough DBP measurement before uptitration to telmisartan 80mg and amlodipine 10mg compared to first trough DBP taken after uptitration. Uptitration could be based DBP\\>90 or investigator opinion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"306","spread":null},{"groupId":"OG001","value":"168","spread":null},{"groupId":"OG002","value":"474","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"324","spread":null},{"groupId":"OG001","value":"258","spread":null},{"groupId":"OG002","value":"582","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":838},"commonTop":[]}}}